Drug resistance detection result of HIV1 patients who failed in antiviral therapy in Jiangsu Province

Abstract:

ObjectiveTo investigate drug resistance of HIV1 infected people who failed in antiviral therapy in Jiangsu Province from 2010 to 2014, and provide reference for clinical antiviral therapy.MethodsBased on the network of drug resistance detection laboratories, detection results of HIV1 genotype resistance in Jiangsu Province from 2010 to 2014 were collected, drug resistance, drug resistance gene loci and virus gene subtypes in different years were statistically analyzed.ResultsFrom 2010 to 2014, 74, 113, 197, 278, and 346 specimens were included, rates of specimens with resistance detection results were 68.92%, 48.67%, 51.27%, 52.52%, and 57.80% respectively. The main HIV1resistant drugs were similar in each year, nucleoside drugs were mainly lamivudine(3TC), abacavir(ABC), didanosine(DDI), and emtricitabine(FTC), nonnucleoside drugs were mainly efavirenz(EFV) and nevirapine(NVP). Drug resistance of HIV1 to protease drugs was quite different, resistance rate of currently used lopinavir/ritonavir(LPV/r) was less than 1%. The major drug resistance loci of HIV1 in four years were 184, 181, 190, and 103 respectively, 184 mutation mainly caused 3TC and FTC resistance, while 181, 190, and 103 mutation were associated with EFV and NVP resistance. HIV1 gene subtype was mainly CRF01_AE, which showed an upward trend.ConclusionThere is an increasing trend of resistance rate of HIV1 genotype in HIVinfected patients who failed in antiviral therapy in Jiangsu Province, drug resistance detection for patients receiving antiviral therapy should be strengthened, so as to adjust antiviral treatment scheme in time.